Search

everythinglearnresearchcommunity

for

Search:↓

A 21-year-old shares progress 1.5 months after starting finasteride (0.5 mg every other day) with no side effects, using minoxidil for beard growth, rosemary oil, and weekly microneedling. They report healthier hair texture and positive feedback from family.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.

The conversation is about the best vehicle for RU58841, comparing trichosol and Garnier/Vichy Stemoxydine, avoiding propylene glycol (PG) or ethanol due to previous scalp damage. The user is also seeking sources for these products in the EU.

Exploring hair loss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgen receptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.

The user shared their 5-year progress using finasteride and topical minoxidil for hair growth, noting initial success but recent thinning and side effects. They plan to switch to dutasteride and oral minoxidil, addressing low iron levels and monitoring potential side effects.

A user shared progress after 5 months on oral finasteride (1mg) and minoxidil (2.5mg), noting improvements despite minimal temple growth. They experienced shedding initially but reported no side effects, and others shared similar experiences and additional treatments like hair serums.

The conversation discusses the use of 12.5mg cyproterone every other day for hair loss. There's a concern about reducing testosterone potentially increasing DHT and negatively affecting hair.

The safety of combining alfatradiol and fluridil with finasteride as a potential treatment for male pattern baldness, which is approved in the European Union. Other treatments such as minoxidil and RU58841 were also discussed.

Tazarotene may be more effective than tretinoin when combined with topical minoxidil for hair loss due to its selective binding to RAR-beta and gamma, though it can cause irritation. Tazarotene's potency can lead to indirect inflammatory reactions despite potentially causing less irritation than tretinoin.

User shares progress after 4 months of using finasteride and dermarolling, with occasional use of coconut and rosemary oil. They aim to stop hair loss and hope for increased top density.

The user has been using 0.5 Dutasteride and 2.5 Oral Minoxidil for 5 months, along with The Ordinary Hair Serum, and is seeing gradual hair improvement. They skipped Finasteride due to severe hair loss and are considering a hair transplant if needed.

A user shared their 5-month hair regrowth progress using 0.5mg Dutasteride daily and 5% Minoxidil foam twice daily, reporting significant improvement despite initial shedding. Other users discussed their experiences with similar treatments, noting varied results and side effects, with some emphasizing the need for long-term commitment to maintain hair growth.

The conversation discusses using a 5% Topical Minoxidil with 0.01% Tretinoin serum for hair loss, noting its lack of propylene glycol to avoid itchiness and greasiness. Users share experiences with different Minoxidil formulations and discuss the effectiveness and stability of Tretinoin in various forms.

A 22-year-old male experiencing diffuse hair thinning has been using finasteride, initially at 0.5mg and then 1mg daily, but sees no improvement. Despite correcting a vitamin D deficiency and noticing some new hair growth, he questions the effectiveness of finasteride.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

The conversation discusses hair loss treatments, specifically oral minoxidil (2.5mg), dutasteride (0.5mg every other day), and ketoconazole. The user reports slow progress but significant hair growth after adding ketoconazole to their routine.

The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.

A 22-year-old resumed using finasteride, minoxidil, and a 0.5mm dermaroller after stopping for two years, experiencing positive results and improved mood. The discussion includes debates on the effects of finasteride on neurosteroids and the optimal dermaroller needle length for hair regrowth.

A user shared their experience using 5% minoxidil twice daily, 1 mg finasteride daily, and weekly derma stamping for hair loss, noting no crown thinning but front diffuse thinning and hairline issues. They experienced fewer side effects on 0.5 mg finasteride but returned to 1 mg, and did not experience shedding after starting treatment.

RU58841 5% is theoretically equivalent to 2mg of dutasteride for hair loss treatment, with RU58841 offering higher potential but more variability due to absorption issues. Users discuss the effectiveness of RU58841 and dutasteride, with some preferring dutasteride for consistent results and others finding success with RU58841.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

A user is considering switching from regular 5% minoxidil foam to a compounded 5% minoxidil spray with added caffeine, melatonin, and tretinoin for easier application and potentially better results. Another user mentions that tretinoin can enhance minoxidil's effectiveness by converting it to its active form.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

The conversation is about the delay in the release of GT20029 phase 2 results by Kintor. It also mentions Minoxidil, finasteride, and RU58841 as treatments for hair loss.

User discusses a promising topical Procyanidin B2 treatment for hair loss. Users share mixed experiences and mention effective treatments like finasteride, minoxidil, and LLLT.

Switching from tretinoin to tazarotene with minoxidil led to new hair regrowth after years of maintenance. Tazarotene's selectivity and higher concentration might be more effective for hair growth.

The user is experiencing positive hair regrowth after two months of using oral finasteride (0.5 mg) and minoxidil (2.5 mg) and is considering a hair transplant. They are seeking advice on surgeons closer to the U.S. and discussing potential side effects and alternative treatments.

A user shared their 5-month progress using topical minoxidil and finasteride for hair loss. Others congratulated and suggested a haircut style.

A 32-year-old male with diffuse thinning and seborrheic dermatitis has been using finasteride for 8 months without improvement. He is considering COQ10 + PQQ supplements for scalp inflammation and hair loss.

The user is considering switching from a topical minoxidil and finasteride solution to oral minoxidil to improve hair growth, while maintaining oral finasteride. They are concerned about potential shedding and whether they can maintain any new growth.